These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 10868865

  • 21. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE, Mohideen P, Fiedorek FT.
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [Abstract] [Full Text] [Related]

  • 22. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
    Murase Y, Wakasugi T, Yagi K, Mabuchi H.
    Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
    [No Abstract] [Full Text] [Related]

  • 23. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ, Bruce S, Fiedorek FT.
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [Abstract] [Full Text] [Related]

  • 24. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM.
    Diabetes Care; 1997 Feb; 20(2):188-93. PubMed ID: 9118772
    [Abstract] [Full Text] [Related]

  • 25. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M.
    Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
    [Abstract] [Full Text] [Related]

  • 26. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
    Plosker GL, Faulds D.
    Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
    [Abstract] [Full Text] [Related]

  • 27. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
    [Abstract] [Full Text] [Related]

  • 28. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
    Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza EC, Adachi Y.
    Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
    [Abstract] [Full Text] [Related]

  • 29. [Thiazolidinediones: clinical data and perspectives].
    Blicklé JF.
    Diabetes Metab; 2001 Apr; 27(2 Pt 2):279-85. PubMed ID: 11452222
    [Abstract] [Full Text] [Related]

  • 30. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group.
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.
    Kuzuya T, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T.
    Diabetes Res Clin Pract; 1998 Aug; 41(2):121-9. PubMed ID: 9789718
    [Abstract] [Full Text] [Related]

  • 34. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
    Schuster D, Gaillard T, Rhinesmith S, Habash D, Osei K.
    Metabolism; 2003 Sep; 52(9):1211-7. PubMed ID: 14506629
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
    Foot EA, Eastmond R.
    Diabetes Res Clin Pract; 1997 Oct; 38(1):41-51. PubMed ID: 9347245
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of troglitazone on body fat distribution in type 2 diabetes.
    Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K.
    Diabetes Care; 2000 Aug; 23(8):1067-71. PubMed ID: 10937499
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M, Wasada T, Katsumori K, Watanabe-Takahashi C, Kamatani N, Iwamoto Y.
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract] [Full Text] [Related]

  • 40. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S, Yanagisawa K, Kanamuro R, Teno S, Iwamoto Y.
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.